Discerning Risk of Disease Transition in Relatives of Systemic Lupus Erythematosus Patients Utilizing Soluble Mediators and Clinical Features

Arthritis and Rheumatology

Volumn 69, Issue 3, 2017, Pages 630-642

  Munroe, Melissa E ^a   Young, Kendra A ^b   Kamen, Diane L ^c   Guthridge, Joel M ^a   Niewold, Timothy B ^d   Costenbader, Karen H ^e   Weisman, Michael H ^f   Ishimori, Mariko L ^f   Wallace, Daniel J ^f   Gilkeson, Gary S ^c   Karp, David R ^g   Harley, John B ^h   Norris, Jill M ^b   James, Judith A ⁱ  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b Food Science and Human Nutrition   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d MAYO CLINIC   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f CEDARS SINAI MEDICAL CENTER   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; B CELL ACTIVATING FACTOR; INTERLEUKIN 10; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; STEM CELL FACTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR RECEPTOR 2; AUTACOID;

ADULT; ARTICLE; BLOOD RELATIVE; BLOOD SAMPLING; CLINICAL FEATURE; CONNECTIVE TISSUE DISEASE SCREENING QUESTIONNAIRE; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MEDIATOR RELEASE; MIDDLE AGED; PREDICTIVE VALUE; PRIORITY JOURNAL; QUESTIONNAIRE; RISK ASSESSMENT; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS; BLOOD; GENETICS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

AUTOANTIBODIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION MEDIATORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; RISK ASSESSMENT;

EID: 85014073019     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.40004     Document Type: Article

References (49)

1. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008;58:15–25.
2. Nokoff N, Rewers M. Pathogenesis of type 1 diabetes: lessons from natural history studies of high-risk individuals. Ann N Y Acad Sci 2013;1281:1–15.
3. Tsokos GC. Systemic lupus erythematosus. N Engl J Med 2011;365:2110–21.
4. Hughes-Austin JM, Deane KD, Derber LA, Kolfenbach JR, Zerbe GO, Sokolove J, et al. Multiple cytokines and chemokines are associated with rheumatoid arthritis-related autoimmunity in first-degree relatives without rheumatoid arthritis: Studies of the Aetiology of Rheumatoid Arthritis (SERA). Ann Rheum Dis 2013;72:901–7.
5. Urowitz MB, Gladman DD, Ibanez D, Fortin PR, Bae SC, Gordon C, et al. Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res (Hoboken) 2012;64:132–7.
6. Flesher DL, Sun X, Behrens TW, Graham RR, Criswell LA. Recent advances in the genetics of systemic lupus erythematosus. Expert Rev Clin Immunol 2010;6:461–79.
7. Lawrence JS, Martins CL, Drake GL. A family survey of lupus erythematosus. Part 1. Heritability. J Rheumatol 1987;14:913–21.
8. Michel M, Johanet C, Meyer O, Frances C, Wittke F, Michel C, et al. Familial lupus erythematosus: clinical and immunologic features of 125 multiplex families. Medicine (Baltimore) 2001;80:153–8.
9. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003;349:1526–33.
10. Laustrup H, Heegaard NH, Voss A, Green A, Lillevang ST, Junker P. Autoantibodies and self-reported health complaints in relatives of systemic lupus erythematosus patients: a community based approach. Lupus 2004;13:792–9.
11. Van der Linden MW, Westendorp RG, Zidane M, Meheus L, Huizinga TW. Autoantibodies within families of patients with systemic lupus erythematosus are not directed against the same nuclear antigens. J Rheumatol 2001;28:284–7.
12. Bruner BF, Guthridge JM, Lu R, Vidal G, Kelly JA, Robertson JM, et al. Comparison of autoantibody specificities between traditional and bead-based assays in a large, diverse collection of patients with systemic lupus erythematosus and family members. Arthritis Rheum 2012;64:3677–86.
13. Satoh M, Chan EK, Ho LA, Rose KM, Parks CG, Cohn RD, et al. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum 2012;64:2319–27.
14. Rullo OJ, Tsao BP. Recent insights into the genetic basis of systemic lupus erythematosus. Ann Rheum Dis 2013;72 Suppl 2:ii56–61.
15. Munroe ME, Vista ES, Guthridge JM, Thompson LF, Merrill JT, James JA. Proinflammatory adaptive cytokine and shed tumor necrosis factor receptor levels are elevated preceding systemic lupus erythematosus disease flare. Arthritis Rheumatol 2014;66:1888–99.
16. Zouali M, Uy EA. Belimumab therapy in systemic lupus erythematosus. BioDrugs 2013;27:225–35.
17. Oliveira SH, Lukacs NW. Stem cell factor: a hemopoietic cytokine with important targets in asthma. Curr Drug Targets Inflamm Allergy 2003;2:313–8.
18. Ray P, Krishnamoorthy N, Oriss TB, Ray A. Signaling of c-kit in dendritic cells influences adaptive immunity. Ann N Y Acad Sci 2010;1183:104–22.
19. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
20. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271–7.
21. Rasmussen A, Sevier S, Kelly JA, Glenn SB, Aberle T, Cooney CM, et al. The lupus family registry and repository. Rheumatology (Oxford) 2011;50:47–59.
22. Kamen DL, Barron M, Parker TM, Shaftman SR, Bruner GR, Aberle T, et al. Autoantibody prevalence and lupus characteristics in a unique African American population. Arthritis Rheum 2008;58:1237–47.
23. Karlson EW, Sanchez-Guerrero J, Wright EA, Lew RA, Daltroy LH, Katz JN, et al. A connective tissue disease screening questionnaire for population studies. Ann Epidemiol 1995;5:297–302.
24. Young KA, Terrell DR, Guthridge JM, Kamen DL, Gilkeson GS, Karp DR, et al. Smoking is not associated with autoantibody production in systemic lupus erythematosus patients, unaffected first-degree relatives, nor healthy controls. Lupus 2014;23:360–9.
25. Kuo CF, Grainge MJ, Valdes AM, See LC, Luo SF, Yu KH, et al. Familial aggregation of systemic lupus erythematosus and coaggregation of autoimmune diseases in affected families. JAMA Intern Med 2015;175:1518–26.
26. Robertson JM, James JA. Preclinical systemic lupus erythematosus. Rheum Dis Clin North Am 2014;40:621–35.
27. Olsen NJ, Karp DR. Autoantibodies and SLE: the threshold for disease. Nat Rev Rheumatol 2014;10:181–6.
28. Thanou A, Merrill JT. Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys. Nat Rev Rheumatol 2014;10:23–34.
29. Scapini P, Bazzoni F, Cassatella MA. Regulation of B-cell-activating factor (BAFF)/B lymphocyte stimulator (BLyS) expression in human neutrophils. Immunol Lett 2008;116:1–6.
30. Lee PY, Li Y, Kumagai Y, Xu Y, Weinstein JS, Kellner ES, et al. Type I interferon modulates monocyte recruitment and maturation in chronic inflammation. Am J Pathol 2009;175:2023–33.
31. Yan B, Ye S, Chen G, Kuang M, Shen N, Chen S. Dysfunctional CD4+,CD25+ regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon-α–producing antigen-presenting cells. Arthritis Rheum 2008;58:801–12.
32. Vargas-Rojas MI, Crispin JC, Richaud-Patin Y, Alcocer-Varela J. Quantitative and qualitative normal regulatory T cells are not capable of inducing suppression in SLE patients due to T-cell resistance. Lupus 2008;17:289–94.
33. Okamoto A, Fujio K, Okamura T, Yamamoto K. Regulatory T-cell-associated cytokines in systemic lupus erythematosus. J Biomed Biotechnol 2011;2011:463412.
34. Fesel C, Barreto M, Ferreira RC, Costa N, Venda LL, Pereira C, et al. Compensatory T-cell regulation in unaffected relatives of SLE patients, and opposite IL-2/CD25-mediated effects suggested by coreferentiality modeling. PLoS One 2012;7:e33992.
35. Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK. High serum IFN-α activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun 2007;8:492–502.
36. Llorente L, Richaud-Patin Y, Couderc J, Alarcon-Segovia D, Ruiz-Soto R, Alcocer-Castillejos N, et al. Dysregulation of interleukin-10 production in relatives of patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:1429–35.
37. Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677–86.
38. Lu R, Munroe ME, Guthridge JM, Bean KM, Fife DA, Chen H, et al. Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies. J Autoimmun 2016;74:182–93.
39. Munroe ME, Lu R, Zhao YD, Fife DA, Robertson JM, Guthridge JM, et al. Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. Ann Rheum Dis 2016;75:2014–21.
40. Kamen DL. Environmental influences on systemic lupus erythematosus expression. Rheum Dis Clin North Am 2014;40:401–12, vii.
41. Costenbader KH, Schur PH. We need better classification and terminology for “people at high risk of or in the process of developing lupus” [editorial]. Arthritis Care Res (Hoboken) 2015;67:593–6.
42. Meacock R, Dale N, Harrison MJ. The humanistic and economic burden of systemic lupus erythematosus: a systematic review. Pharmacoeconomics 2013;31:49–61.
43. Moss ML, White JM, Lambert MH, Andrews RC. TACE and other ADAM proteases as targets for drug discovery. Drug Discov Today 2001;6:417–26.
44. Kan HJ, Song X, Johnson BH, Bechtel B, O'Sullivan D, Molta CT. Healthcare utilization and costs of systemic lupus erythematosus in Medicaid. Biomed Res Int 2013;2013:808391.
45. Ugarte-Gil MF, Alarcon GS. Systemic lupus erythematosus: a therapeutic challenge for the XXI century. Clin Rheumatol 2014;33:441–50.
46. Bluestone JA, Bour-Jordan H. Current and future immunomodulation strategies to restore tolerance in autoimmune diseases. Cold Spring Harb Perspect Biol 2012;4.
47. Molad Y, Gorshtein A, Wysenbeek AJ, Guedj D, Majadla R, Weinberger A, et al. Protective effect of hydroxychloroquine in systemic lupus erythematosus: prospective long-term study of an Israeli cohort. Lupus 2002;11:356–61.
48. James JA, Kim-Howard XR, Bruner BF, Jonsson MK, McClain MT, Arbuckle MR, et al. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus 2007;16:401–9.
49. Al Sawah S, Zhang X, Zhu B, Magder LS, Foster SA, Iikuni N, et al. Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus: the Hopkins lupus cohort. Lupus Sci Med 2015;2:e000066.